SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL

https://storage.unitedwebnetwork.com/files/1099/749e9963c0c71fa9b940340eff70aa70.pdf

Stephanie Moody stephanie.moody@travere.com Travere Therapeutics, Inc. Biostatistics San Diego

Neeraj Dhaun bean.dhaun@ed.ac.uk Royal Infirmary of Edinburgh Department of Renal Medicine Edinburgh

Siân Griffin sian.griffin2@wales.nhs.uk University Hospital of Wales Department of Nephrology and Transplantation Cardiff

Alexandra Howson alexandra.l.howson@uhl-tr.nhs.uk University of Leicester & Leicester General Hospital N/A Leicester

Radko Komers radko.komers@travere.com Travere Therapeutics, Inc. Clinical Development, Nephrology San Diego

Alex Mercer alex.mercer@travere.com JAMCO Pharma Consulting N/A Stockholm

Matthew Sayer msayer2@exseed.ed.ac.uk Royal Infirmary of Edinburgh Department of Renal Medicine Edinburgh

Smeeta Sinha smeeta.sinha@nca.nhs.uk Salford Royal Hospital Northern Care Alliance NHS Foundation Trust Department of Renal Medicine Salford

Lisa Willcocks lisa.willcocks@nhs.net Addenbrooke's Hospital, Cambridge University Hospitals Department of Renal Medicine Cambridge

Jonathan Barratt jb81@le.ac.uk University of Leicester & Leicester General Hospital Department of Nephrology Leicester